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Background: It has been hypothesised that intrauterine exposures are important for subsequent prostate cancer risk. Prior
epidemiological studies have used birthweight as a proxy of cumulative intrauterine exposures to test this hypothesis, but results
have been inconsistent partly because of limited statistical power.
Methods: We investigated birthweight in relation to prostate cancer in the Medical Research Council (MRC) National Survey of
Health and Development (NSHD) using Cox proportional hazards models. We then conducted a meta-analysis of birthweight in
relation to total and aggressive/lethal prostate cancer risks, combining results from the NSHD analysis with 13 additional studies
on this relationship identified from a systematic search in four major scientific literature databases through January 2015.
Results: Random-effects models found that per kg increase in birthweight was positively associated with total (OR¼ 1.02, 95%
confidence interval (95% CI)¼ 1.00, 1.05; I2¼ 13%) and aggressive/lethal prostate cancer (OR¼ 1.08, 95% CI¼ 0.99, 1.19; I2¼ 40%).
Sensitivity analyses restricted to studies with birthweight extracted from medical records demonstrated stronger positive
associations with total (OR¼ 1.11, 95% CI¼ 1.03, 1.19; I2¼ 0%) and aggressive/lethal (OR¼ 1.37, 95% CI¼ 1.09, 1.74; I2¼ 0%)
prostate cancer. These studies heavily overlapped with those based in Nordic countries.
Conclusions: This study provides evidence that heavier birthweight may be associated with modest increased risks of total and
aggressive/lethal prostate cancer, which supports the hypothesis that intrauterine exposures may be related to subsequent
prostate cancer risks.
Prostate cancer is a significant public health burden and a major
cause of morbidity and mortality among men worldwide. Few risk
factors have been established for prostate cancer including
advancing age, African ancestry, a family history of this
malignancy and certain genetic polymorphisms (Al Olama et al,
2014). This may be partly owing to the fact that a majority of
studies have focused on mid- to later-life exposures, and therefore
may have missed putative aetiologically relevant time-windows,
specifically early developmental stages of the prostate gland
(Sutcliffe and Colditz, 2013). It has been hypothesised that
intrauterine exposures may contribute to subsequent increased
risk of prostate cancer (Ekbom, 1998), given that the hormonal and
metabolic environment during pregnancy influences the physiolo-
gical development of the prostate gland and may modulate
hormonal sensitivity and prostate cancer risks in adult men
(Ross and Henderson, 1994; Shibata and Minn, 2000). Although
the biologic mechanisms underpinning a possible in utero origin of
prostate cancer are not fully understood, intrauterine sex steroid
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hormones, insulin-like growth factors (IGFs) and elevated number
of fetal stem cells (‘stem cell burden’ hypothesis; Ekbom, 1998)
have been suggested to have important roles.
Direct epidemiological evidence linking intrauterine hormones
and increased stem cell numbers to prostate cancer risk is sparse,
likely because of the long latency period of tumour development
and the challenge of accounting for changes in environmental
factors after birth. Therefore, prior epidemiological studies have
used birthweight as a proxy for cumulative intrauterine exposures
for multiple chronic disease outcomes (Kuh and Ben-Shlomo,
2004). For example, birthweight has been extensively studied in
relation to breast cancer and a recent meta-analysis suggested a
positive dose–response relationship (dos Santos Silva et al, 2008).
In relation to prostate cancer – another hormonally related
malignancy – an early ecologic study demonstrated that mortality
rates were positively correlated with country-level birthweight
(Lawson, 1998). However, results to date from epidemiological
studies of birthweight and prostate cancer risks have not
consistently endorsed this relationship, partly because of insuffi-
cient statistical power, especially for aggressive/lethal prostate
cancers, which are of greatest clinical relevance. Therefore, we
performed a cohort analysis using the Medical Research Council
(MRC) National Survey of Health and Development (NSHD),
which extracted birthweight from medical records within a few
weeks of delivery in 1946 and has subsequently accumulated nearly
70 years of follow-up. In addition, to provide a comprehensive
assessment of birthweight in relation to total and aggressive/lethal
prostate cancer risks, we conducted a systematic review and meta-
analysis, combining results from our smaller NSHD analysis with
those prior studies identified from systematic review.
MATERIALS AND METHODS
National Survey of Health and Development. We performed a
cohort analysis in the NSHD birth cohort. A detailed description of
this birth cohort has been published previously (Wadsworth et al,
2006). In brief, this cohort is a socially stratified and representative
sample (N¼ 5362) of single live births in England, Scotland or
Wales born in March 1946 and followed up ever since. Birthweight
data were extracted from medical records within a few weeks of
delivery. Characteristics of cohort members and their parents have
been prospectively collected at follow-ups throughout life. Cohort
members have been flagged on the National Health Service Central
Register since 1971 (at the age of 25 years) for notification of
cancer diagnoses, deaths and emigrations. We used Cox propor-
tional hazards models with age as the underlying time scale to
estimate hazard ratio (HRs) and 95% confidence intervals (CIs) of
continuous (per kg) and categorical birthweight (o3000, 3000–
3499, 3500–3999 andX4000 g) in relation to total prostate cancer.
Follow-up of this analysis started at the age of 25 years when
cancer register data became available, and continued until prostate
cancer diagnosis, death, emigration or age 67 years (i.e., until
November 2014, the most recent date of available cancer registry
data), whichever occurred earlier. We included 2791 men in this
analysis, after excluding 2547 females, 17 men without birthweight
information and 7 without follow-up information.
Literature search. To complement the NSHD analysis and
increase the statistical power, we also conducted a systematic
review on the relationship between birthweight and prostate cancer
risks. Four major scientific literature databases (PubMed (National
Centre for Biotechnology Information, US National Library
of Medicine, Bethesda, MD, USA), EMBASE (Elsevier BV,
Amsterdam, The Netherlands), Scopus (Elsevier BV), Web of Science
(Thomson Reuters, New York, NY, USA)) were systematically searched
through January 2015 by a trained clinical informationist (JW).
No date or language restrictions were applied. Search terms
incorporated a wide array of variables for, or related to, birthweight
and prostate cancer or cancer in general. Search strategies are
available from the authors on request. Two reviewers (CKZ and
MBC) independently assessed titles, abstracts and keywords to
select potentially relevant studies from retrieved references.
Discordant selections were resolved by consensus. The full text
of any original contribution that indicated a potential to contain
data on birthweight and prostate cancer, or of any review on
prostate cancer aetiology, was retrieved. Bibliographies of retrieved
full-text articles were also reviewed to identify references that may
have been missed or absent from the databases used. We contacted
corresponding authors for additional data if their publications did
not present adequate information necessary for meta-analysis.
References were compiled and managed using Endnote X7. To be
included in this meta-analysis, a published study had to fulfill the
following criteria: (1) study populations were born as singletons;
(2) have at least 20 cases and 20 controls in the analysis; (3) used a
cohort or case–control study design; and (4) provided risk
estimates with 95% CIs per unit change in birthweight, or
tabulated counts of cases and controls by birthweight category to
allow for log-linear coefficients and standard errors to be estimated
using methods described previously (Chene and Thompson, 1996).
When multiple reports were published with substantial geotem-
poral overlap in the base population, we included the most recent
or best-powered publication. Two reviewers (CKZ and MBC)
independently extracted data from selected articles according to a
standard form created a priori for this study. Differences were
resolved by consensus.
Meta-analysis. For studies reporting results with categorical
birthweight, we calculated individual unadjusted log odds ratios
(ORs) per kg increase in birthweight and their standard errors
using tabulated counts of cases and controls by birthweight
category via methods described previously (Chene and Thompson,
1996). For studies reporting results with continuous birthweight,
we back-calculated log risk estimates per kg and their standard
errors using reported estimates and their 95% CIs. Unadjusted or
minimally adjusted risk estimates were preferred over maximally
adjusted estimates, given the fact that putative confounding factors
showed little or no effect on estimates attained for the relationship
between birthweight and prostate cancer risks in prior studies. This
has the additional benefit of reducing excess heterogeneity
attributable to different model specifications used in published
studies. We pooled study-specific risk estimates using a random-
effects meta-analytic model, and tested for between-study hetero-
geneity in risk estimates using a w2 test based on the Q statistic, as
well as the I2 statistic and its 95% uncertainty interval (95% UI). To
evaluate publication bias, we visually inspected the symmetry of
funnel plots and quantitatively tested the bias using Begg’s rank
correlation test and Egger’s linear regression test. To evaluate the
influence of individual studies on the summary estimates, we
performed influence analyses by leaving out one study at a time
and re-estimating the summary estimates. We also performed
meta-regression by separately including study-level covariates,
such as birthweight source (medical records vs reported), country
(Nordic vs non-Nordic), design (cohort/nested case–control vs
population-based case–control), mid-birth year (p1945 vs41945;
The World War II ends in 1945), mean/median age at diagnosis
(p65 vs 465 years) and adjustment status (no/minimal vs
maximum), which were specified a priori. Finally, analyses were
also conducted using fixed-effects models for the purpose of
comparison and comprehensiveness. Meta-analyses were con-
ducted separately for total and aggressive/lethal prostate cancers.
All statistical analyses were performed using Stata version 13 (Stata
Corp., College Station, TX, USA). Two-sided P-valueso0.05 were
considered statistically significant.
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RESULTS
NSHD results. Of the 2791 men in the NSHD birth cohort, 81
were diagnosed with prostate cancer through November 2014, of
which 24 (30%) were diagnosed at ages younger than 60 years.
Characteristics by event status are shown in Supplementary
Table 1. Generally, these characteristics were evenly distributed
by event status, except that fathers and maternal grandfathers of
prostate cancer cases were more likely to have non-manual jobs,
and mothers were more likely to have higher education compared
with those of controls. Hazard ratios and 95% CIs estimated
from Cox proportional hazards models are shown in
Supplementary Table 2. In this NSHD analysis, neither continuous
(ORper kg increase¼ 0.84, 95% CI¼ 0.56, 1.27) nor categorical
(OR3000–3499 vs o3000 g¼ 1.03, 95% CI¼ 0.54, 1.95; OR3500–3999 vs
o3000 g¼ 0.98, 95% CI¼ 0.51, 1.86; ORX4000 vs o3000 g¼ 0.93, 95%
CI¼ 0.42, 2.06) birthweight were significantly associated
with prostate cancer. The proportional hazards assumptions
held with nonsignificant Schoenfeld residuals test
(Pcontinuous birthweight¼ 0.103; Pcategorical birthweight¼ 0.478). As
adjustment for father’s and maternal grandfather’s occupation as
well as mother’s education did not materially change the results
(Supplementary Table 2), we used unadjusted risk estimates in
subsequent meta-analysis.
Literature search and study characteristics. A flow chart for this
systematic review is shown in Figure 1. After independently
screening titles, abstracts and key words, we deemed 49 articles to
be potentially eligible and retrieved their full texts. After reviewing
the full texts and their bibliographies, we included 14 studies in
total (Ekbom et al, 1996, 2000; Boland et al, 2003; Kajantie et al,
2005; McCormack et al, 2005; Nilsen et al, 2005; Eriksson et al,
2007; Sutcliffe et al, 2007; Parent et al, 2008; Barker et al, 2012;
Lope et al, 2012; Cook et al, 2013; Gerdtsson et al, 2015) including
the NSHD analysis presented herein for qualitative and quantita-
tive synthesis, 8 of which were cohort in design (Kajantie et al,
2005; McCormack et al, 2005; Nilsen et al, 2005; Eriksson et al,
2007; Sutcliffe et al, 2007; Barker et al, 2012; Cook et al, 2013)
including the NSHD analysis presented herein, 3 were nested case–
control (Ekbom et al, 1996, 2000; Gerdtsson et al, 2015) and 3 were
population-based case–control (Boland et al, 2003; Parent et al,
2008; Lope et al, 2012). Four of these 14 included studies used
reported birthweight (Sutcliffe et al, 2007; Parent et al, 2008; Lope
et al, 2012; Cook et al, 2013), 9 were conducted in Nordic countries
(Ekbom et al, 1996, 2000; Kajantie et al, 2005; McCormack et al,
2005; Nilsen et al, 2005; Eriksson et al, 2007; Barker et al, 2012;
Cook et al, 2013; Gerdtsson et al, 2015), and 8 reported the
association between birthweight and aggressive/lethal prostate
cancers (Ekbom et al, 1996; Kajantie et al, 2005; Nilsen et al, 2005;
Eriksson et al, 2007; Sutcliffe et al, 2007; Parent et al, 2008; Lope
et al, 2012; Gerdtsson et al, 2015). Among those eight studies with
subtype results, the Finnish study by Kajantie et al (2005) was the
only study that did not report the association with total incident
prostate cancer. Among excluded studies, five overlapped with the
base populations of included studies (Tibblin et al, 1995; Platz et al,
1998; Ahlgren et al, 2007; Lahmann et al, 2010, 2012).
Characteristics of included studies on birthweight in relation to
prostate cancer risks are shown in Table 1.
Meta-analysis
Total prostate cancer. We pooled risk estimates from 13 studies
for the risk of total prostate cancer per kg increase in birthweight
using a random-effects model, and found that birthweight was
associated with a small increased risk of the outcome (OR¼ 1.02,
95% CI¼ 1.00, 1.05; P¼ 0.045) (Figure 2). Publication bias was
unlikely given the nonsignificant Begg’s (P¼ 0.583) and Egger’s
901 records identified through
literature search
355 records after duplicates removed
355 records screened 306 records excluded
49 full-text articles
assessed for eligibility
14 studies included in
qualitative synthesis
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Figure 1. Flow chart for systematic review.







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































BRITISH JOURNAL OF CANCER Birthweight and prostate cancer
4 www.bjcancer.com |DOI:10.1038/bjc.2016.38
(P¼ 0.202) tests, although the funnel plot appeared slightly
asymmetric (Supplementary Figure 1). Omission of one study at
a time did not materially change the summary risk estimate
(Supplementary Table 3). In particular, when Sutcliffe et al (2007)
or Parent et al (2008) – which had the greatest weights – were
excluded, the summary risk estimates did not deviate from the
overall risk estimate. Subgroup analyses of study-level variables
showed that birthweight source (P¼ 0.014) and country
(P¼ 0.005) may partially explain the small amount of between-
study heterogeneity detected, with higher summary risk estimates
for studies that used medical records to ascertain birthweight
(ORper kg increase¼ 1.11, 95% CI¼ 1.03, 1.19) and studies in Nordic
countries (ORper kg increase¼ 1.10, 95% CI¼ 1.04, 1.16) (Table 2).
Seven of the nine studies that used medical records to ascertain
birthweight were based in Nordic countries. Given the hetero-
geneity test was not statistically significant (P¼ 0.312) with
I2¼ 13% (95% UI¼ 0%, 52%), we performed sensitivity analyses
using fixed-effects models, which provided similar overall (ORper kg
increase¼ 1.02, 95% CI¼ 1.00, 1.03; P¼ 0.028) and subgroup
summary estimates (Supplementary Table 4).
Aggressive/lethal prostate cancer. We separately conducted a
meta-analysis using a random-effects model of eight studies that
provided birthweight in relation to aggressive/lethal prostate
cancer risk. We found that per kg increase in birthweight seemed
to be associated with an 8% increased risk of aggressive/lethal
disease (OR¼ 1.08, 95% CI¼ 0.99, 1.18; P¼ 0.076), although the
association was not statistically significant (Figure 3). Publication
bias was suggested by the asymmetry of the funnel plot
(Supplementary Figure 2), yet objective judgment is difficult with
only eight studies and Begg’s (P¼ 0.266) and Egger’s (P¼ 0.054)
tests were not statistically significant. In influence analyses, the
study by Parent et al (2008) was found to have an influence on the
summary estimate, as the estimate became statistically significant
and increased by 6% (OR¼ 1.14, 95% CI¼ 1.01, 1.28) once such
study was removed (Supplementary Table 3). Of the eight studies
included in this analysis, all Nordic studies had retrieved
birthweight information from medical records, whereas all non-
Nordic studies used reported birthweight. Subgroup analyses of the
study-level variables showed that the moderate between-study
heterogeneity (I2¼ 40%, 95% UI¼ 0%, 73%; P¼ 0.115) may be
explained by birthweight source/study country (P¼ 0.020) and
study design (P¼ 0.012), with higher summary estimates for
aggressive/lethal prostate cancer when restricted to Nordic studies
that used medical record birthweight (ORper kg increase¼ 1.37,
95% CI¼ 1.09, 1.74), or studies in cohort/nested case–control
designs (ORper kg increase¼ 1.14, 95% CI¼ 1.05, 1.24) (Table 2).
For comparison and comprehensiveness, we performed
fixed-effects meta-analysis, in which we found a slightly
smaller but statistically significant overall summary result
(ORper kg increase¼ 1.04, 95% CI¼ 1.00, 1.08; P¼ 0.026) as well as
consistent subgroup results (Supplementary Table 4).
DISCUSSION
We did not find a statistically significant association between
birthweight and total prostate cancer risk in the NSHD birth
cohort, which may be because of the small number of events. Also,
we did not have information on tumour characteristics to evaluate
the association with aggressive/lethal prostate cancer in this birth
cohort. However, our systematic review and meta-analysis suggests
that greater birthweight is associated with small increased risks of
total and aggressive/lethal prostate cancer. We detected a small
amount of heterogeneity for total prostate cancer (I2¼ 13%) but a
moderate amount for aggressive/lethal disease (I2¼ 40%). The
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cancer were stronger when restricted to studies that used
birthweight extracted from medical records or studies that were
based in Nordic countries.
Although our meta-analysis estimated positive associations
between birthweight and risks of total and aggressive/lethal
prostate cancer, the magnitude of these associations was modest.
However, we believe this modest magnitude is consistent with use
of a proxy measure of the intrauterine environment rather than the
possible causal exposure. Similar modest associations have also
been observed for other in utero markers and prostate cancer risk,
consistent with our findings for birthweight. For example, shorter
duration of gestation, which is associated with lower birthweight,
has been inversely associated with prostate cancer risk (Ekbom
et al, 1996), whereas higher parity (X4) and placental weight,
which are both associated with greater birthweight, have been
positively associated with prostate cancer risk (Ekbom et al, 1996,
2000). In addition, taller adult height, another marker correlated
with greater birthweight (Eide et al, 2005), was positively associated
with total (ORper 5 cm¼ 1.04, 95% CI¼ 1.03, 1.05) and advanced
(ORper 5 cm¼ 1.04, 95% CI¼ 1.02, 1.06) prostate cancer in a recent
meta-analysis (World Cancer Research Fund International, 2014).
Whether the link between birthweight and prostate cancer risks is
mediated in full or part by adult height requires further
investigation. Although birthweight is frequently used as a proxy
of intrauterine exposures, the biologic mechanisms underlying a
possible birthweight–prostate cancer association are not fully
understood. Endogenous hormones, such as sex steroid hormones
(Petridou et al, 1990; Peck et al, 2003) and IGFs (Orbak et al, 2001;
Skalkidou et al, 2002; Davidson et al, 2006), and increased fetal
stem cell burden (Strohsnitter et al, 2008; Capittini et al, 2011) in
utero – all of which have demonstrated correlations with
birthweight – have been hypothesised to modulate hormonal
sensitivity and the risk of prostate cancer in adulthood.
Maternal and fetal sex steroid hormones act in concert in
prenatal development, and homeostasis of both is essential for
subsequent prostate health. The development of the prostate gland
is androgen-dependent. Prostatic buds emerge from the urogenital
sinus, which expresses androgen receptors stimulated by testicular
androgens at approximately the tenth week of gestation (Cunha
et al, 1987). It has been speculated that increased testosterone
exposure in utero might reset the hypothalamic-pituitary-testicular
feedback axis, leading to increased androgen secretion later in life.
This hypothesis has been proposed to explain racial variation in
prostate cancer risk (Ross and Henderson, 1994), as higher
testosterone and oestradiol levels have been found in early
gestational blood from African American than Caucasian women
(Henderson et al, 1988; Potischman et al, 2005), higher
testosterone to sex hormone-binding globulin concentration ratios
have been found in cord blood from African American than their
Caucasian male neonates (Rohrmann et al, 2009), and higher age-
adjusted free testosterone concentrations were found in healthy
adult African American men than their Caucasian counterparts in
a recent meta-analysis (Richard et al, 2014). On the other hand, as
fetal androgen levels decline and maternal oestrogen levels rise in
the third trimester, exposure to excessive oestrogens can induce
aberrant proliferation of the prostatic epithelium, which may lead
to squamous metaplasia in the fetus, although this pathological
change regresses rapidly after birth when maternal oestrogens
plummet (Ellem and Risbridger, 2009). Evidence for oestrogen
carcinogenesis has been consistently documented in rodent studies,
which have demonstrated that exposure to high-dose diethylstil-
bestrol and 17 b-oestradiol during development can reprogramme
the prostate gland and increase its susceptibility to carcinogenesis
with ageing (Prins and Ho, 2010).
Other hormones regulating growth and metabolism may also
have roles in subsequent prostate carcinogenesis. Insulin-like
growth factors are required for prostate gland development (Ruan
et al, 1999), and adult circulating concentrations have been
positively associated with prostate cancer risk (Rowlands et al,
2009). Moreover, IGF-1 and IGFBP-3 concentrations in cord blood
have been correlated with increased number of stem cell measures,
which may confer higher susceptibility to later malignant
transformation, and to a lesser extent, oestradiol, oestriol and
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Figure 2. Birthweight (per kg) in relation to total prostate cancer risk by birthweight source using a random-effects model (N¼ 13).
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However, contrary to the expected direction of the association
based on racial variation in prostate cancer risk, one study found
that African-American neonates had lower concentrations of IGFs
in cord blood than Caucasians (Rohrmann et al, 2009). Finally,
leptin (Lai et al, 2011) and vitamin D (Eichholzer et al, 2013) cord
blood levels were also similar in African-American and Caucasian
neonates, suggesting that intrauterine exposure to these molecules
is unlikely to explain racial differences in prostate cancer risk in
adulthood.
This meta-analysis has several limitations that merit discussion.
We cannot rule out measurement error in the three studies that
used self-reported birthweight (Parent et al, 2008; Lope et al, 2012;
Sutcliffe, 2007), given the fair-to-moderate agreement between self-
reported and birth certificate-ascertained birthweight in prior
validation studies (Jaworowicz et al, 2010); one cohort study that
used maternal-reported birthweight (Cook et al, 2013) may have
been subject to a lesser degree of measurement error (Adegboye
and Heitmann, 2008). The stronger association observed in the
subgroup of medical record-ascertained birthweight indirectly
supports the possible existence of measurement error. Further-
more, we cannot exclude recall bias for two of these studies that
ascertained birthweight information by self-report after prostate
cancer diagnosis in a population-based case–control design (Parent
et al, 2008; Lope et al, 2012), given that the summary estimate
significantly increased by 10% (ORper kg increase¼ 1.14, 95%
CI¼ 1.05, 1.24) for aggressive/lethal prostate cancer after omitting
these two studies, although the summary estimate was not
materially changed for total prostate cancer (ORper kg increase¼ 1.05,
95% CI¼ 1.01, 1.10; P¼ 0.024). Measurement error and recall bias
usually attenuate associations, thus we may have underestimated
the magnitude of the relationships between birthweight and
prostate cancer risks. Second, we extracted/estimated unadjusted
or minimally adjusted risk estimates from the majority of studies
included, even though gestational age, maternal smoking, preg-
nancy-related and neonatal complications (e.g., pre-eclampsia/
eclampsia and jaundice), birth order/parity and maternal anthro-
pometric measures have been hypothesised to confound
birthweight–prostate cancer associations. However, as prior studies
to assess such factors found little or no effect on estimates (Boland
et al, 2003; Nilsen et al, 2005; Eriksson et al, 2007; Zhou et al,
herein), and as adjustment status was not significant in our
subgroup analysis, we do not believe that use of minimally adjusted







I2 95% UIs P-value
Total PCa
Source of birthweight 0.014
Medical records 9 1.11 1.03, 1.19 0 0, 56 0.605
Reported 4 1.01 1.00, 1.03 0 0, 68 0.700
Study country 0.005
Nordic 8 1.10 1.04, 1.16 0 0, 47 0.746
Other 5 1.01 0.99, 1.03 0 0, 49 0.804
Study design 0.178
Cohort/nested case–control 10 1.06 1.01, 1.11 25 0, 64 0.216
Population-based case–control 3 1.01 0.98, 1.03 0 0, 72 0.690
Mid-birth cohort 0.913
p1945 9 1.03 1.00, 1.06 30 0, 67 0.182
41945 4 1.03 0.95, 1.11 0 0, 81 0.491
Mean/median age at diagnosis 0.477
p65 6 1.01 0.99, 1.04 0 0, 61 0.661
465 7 1.06 0.99, 1.14 42 0, 75 0.114
Adjustment status 0.648
No/minimal 10 1.03 1.00, 1.06 30 0, 66 0.173
Maximum 3 1.05 0.97, 1.13 0 0, 61 0.763
Aggressive/lethal PCa
Source of birthweight 0.020
Medical records 5 1.37 1.09, 1.74 0 0, 58 0.735
Reported 3 1.05 0.97, 1.13 51 0, 86 0.129
Study country 0.020
Nordic 5 1.37 1.09, 1.74 0 0, 58 0.735
Other 3 1.05 0.97, 1.13 51 0, 86 0.129
Study design 0.012
Cohort/nested case–control 6 1.14 1.05, 1.24 0 0, 73 0.455
Population-based case–control 2 1.02 0.98, 1.06 0 NA 0.467
Mid-birth cohort 0.265
p1945 7 1.10 1.00, 1.22 44 0, 77 0.095
41945 1 0.92 0.70, 1.21 NA NA NA
Mean/median age at diagnosis 0.291
p65 2 1.02 0.98, 1.06 0 NA 0.609
465 6 1.15 0.99, 1.33 27 0, 69 0.235
Adjustment status 0.358
No/minimal 7 1.08 0.99, 1.18 43 0, 76 0.106
Maximum 1 1.49 0.76, 2.91 NA NA NA
Abbreviations: CI¼ confidence interval; NA¼ not applicable; OR¼odds ratio; PCa¼prostate cancer; UI¼uncertainty interval.
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estimates influenced our conclusions (Table 1). Third, longitudinal
anthropometric measures, such as adult height, were only
ascertained in two of the included studies (Cook et al, 2013;
Gerdtsson et al, 2015). As these studies observed different results
for anthropometric measures, we are unable to evaluate to what
extent the effects of birthweight may be mediated by adult height.
Fourth, we cannot exclude the possibility of publication bias for the
meta-analysis on aggressive/lethal prostate cancer, given that only
eight studies presented results for this subgroup of cases. Last,
studies included in this meta-analysis were primarily conducted in
men with European ancestry, and therefore we were unable to
evaluate whether birthweight is associated with prostate cancer
risks in men with African ancestry.
In conclusion, this systematic review and meta-analysis suggests
that heavier birthweight may be associated with modest increased
risks of total and aggressive/lethal prostate cancer. Novel
approaches and longitudinal data are needed in future birth
cohorts to elucidate biological mechanisms and determine the
aetiological time windows for prostate carcinogenesis.
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